Jason Rivera
Family · Laredo, TXNPI 1114560950
Payments from drug & device makers
Across 115 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$457
- Lilly USA, LLC$311
- AstraZeneca$299
- Bayer$293
- GSK$149
- AbbVie$132
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,65499%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 19 | $457 |
| Lilly USA, LLC | 15 | $311 |
| AstraZeneca | 8 | $299 |
| Bayer | 18 | $293 |
| GSK | 5 | $149 |
| AbbVie | 7 | $132 |
| Amgen | 2 | $123 |
| Novo Nordisk | 6 | $102 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $102 |
| Verona Pharma, Inc. | 4 | $98 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| Phathom Pharmaceuticals, Inc. | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Merck | 3 | $61 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Lundbeck LLC | 1 | $28 |
| Alkermes, Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $26 |
| Phadia US Inc. | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Pfizer | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Cequr Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,674 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $128,865 |
| JardianceEmpagliflozin | 54 | $74,087 |
| LinzessLinaclotide | 66 | $66,904 |
| JanuviaSitagliptin Phosphate | 48 | $59,342 |
| FarxigaDapagliflozin Propanediol | 36 | $46,301 |
| TradjentaLinagliptin | 33 | $43,367 |
| RybelsusSemaglutide | 18 | $41,497 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $34,789 |
| SynjardyEmpagliflozin/Metformin Hcl | 26 | $32,357 |
| MyrbetriqMirabegron | 28 | $31,375 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $29,119 |
| KerendiaFinerenone | 15 | $26,939 |
| EntrestoSacubitril/Valsartan | 12 | $23,930 |
| EliquisApixaban | 16 | $19,242 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $12,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $102 | $170,362103 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $22 | $149,812113 claims |
| MerckJanuvia, Janumet | $61 | $88,46268 claims |
| AbbVieLinzess | $132 | $66,90466 claims |
| AstraZenecaFarxiga | $299 | $46,30136 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $149 | $41,77671 claims |
| BayerKerendia | $293 | $26,93915 claims |
| PfizerEliquis | $15 | $19,24216 claims |
| Lilly USA, LLCTrulicity | $311 | $11,68612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Laredo
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.